Oncology Update

Oncology Update

Diane M. Otte

nursing education
ONF 2012, 39(5), 507-508. DOI: 10.1188/12.ONF.507-508

In a poster discussion session at the American Society of Clinical Oncology meeting in Chicago, IL, Daniel George, MD, of Duke University Medical Center discussed updated results from a phase II study of orteronel, a selective oral 17,20-lyase inhibitor dosed without prednisone in patients with nonmetastatic castrate-resistant prostate cancer and rising prostate-specific antigen (PSA). The primary objective of the study was to determine the percentage of patients achieving a PSA reduction to 0.2 ng/ml or less (undetectable levels) after three months. The study included 39 patients and showed the following results.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.